News tagged with phase iii
New drug extends survival in patients with drug-resistant prostate cancer
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression ...
Feb 01, 2012 |
5 / 5 (1) |
0
|
AML patients have high response rate with vorinostat added to treatment
Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center ...
Dec 13, 2011 |
not rated yet |
0
Study shows new medication effectively treats underlying cause of cystic fibrosis
A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients ...
Nov 02, 2011 |
not rated yet |
0
Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children
First results from a large-scale Phase III trial of RTS,S*, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protec ...
Oct 18, 2011 |
not rated yet |
1
FDG-PET appears promising for predicting prognosis of patients with inoperable NSCLC
The prognosis for patients with stage II and III inoperable non-small cell lung cancer (NSCLC) is poor, with only about 15 percent of patients surviving at five years post-treatment for the disease. While new treatment strategies ...
Oct 05, 2011 |
not rated yet |
0
Company stock prices before public announcements of oncology trial results
Prior knowledge of phase III clinical trials of new drugs and Food and Drug Administration (FDA) regulatory decisions may affect the price of a drug company's stock according to a study published September 26 in the Journal of ...
Sep 26, 2011 |
not rated yet |
0
New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy
Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. Researchers ...
Sep 26, 2011 |
not rated yet |
0
Bone-strengthening drug gives pain relief in prostate cancer bone metastases
Stockholm, Sweden: Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomised Phase III trial of a bisphosphonate drug in these patients has ...
Sep 25, 2011 |
4 / 5 (1) |
0
Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients
Melanoma of the eye (ocular or uveal melanoma) frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients ...
Sep 23, 2011 |
4 / 5 (1) |
0
First Phase III trial of an alpha-pharmaceutical
Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong ...
Sep 23, 2011 |
not rated yet |
0
US approves cell therapy injection for wrinkles
US regulators have approved a new type of therapy that uses a person's own skin cells to create an injectable cosmetic plumper to smooth out laugh lines, Fibrocell Science said Wednesday.
Jun 22, 2011 |
not rated yet |
0
Dengue vaccine could be ready by 2015: Sanofi
French drugs group Sanofi said Friday that its vaccine against dengue, a mosquito-borne infection that kills thousands of people around the world each year, could be launched in about four years.
Medicine & Health / Medications
Jun 10, 2011 |
not rated yet |
0
Large clinical trial finds pirfenidone may help lung function in IPF patients
A large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF.
May 17, 2009 |
5 / 5 (1) |
0
